Fujian Haixi Pharmaceuticals (HKG:2637) said its Hong Kong initial public offering timetable has been delayed as the company needs more time to finalize its listing announcement and secure regulatory clearance, according to a late-Thursday bourse filing.

The company was originally scheduled to release its allocation results on Thursday, ahead of its planned trading debut on the Hong Kong Stock Exchange on Friday.

Fujian Haixi said the revised listing timetable will be announced as soon as practicable once regulatory clearance is secured.

The announcement was expected to include details on the final offer price, subscription levels in the Hong Kong public offering and international placing, and the basis of share allocation.